Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 15/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | METTL14 | Q9HCE5 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014236 | 0.86 | METTL3 (0.50) | METTL3KDM4EMAPTHPGDKMT2A | |
| SCHEMBL22499335 | 0.85 | KDM4E (0.57) | METTL3KDM4EMAPTHPGDKMT2A | |
| SCHEMBL24691325 | 0.84 | KDM4E (0.56) | METTL3KDM4EMAPTHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL22499322 | 0.84 | KDM4E (0.56) | METTL3KDM4EMAPTHPGDKMT2A | |
| SCHEMBL31014222 | 0.83 | PTGS1 (0.45) | METTL3KDM4EMAPTHPGDKMT2A | |
| Lithium Ion SCHEMBL22499045 | 0.83 | METTL3 (0.53) | METTL3KDM4EMAPTHPGDKMT2A | |
| SCHEMBL823315 | 0.80 | ALDH1A1 (0.56) | METTL3KDM4EMAPTHPGDKMT2A | |
| SCHEMBL31253535 | 0.78 | KDM4E (0.40) | METTL3KDM4EMETTL14 | |
| SCHEMBL3958034 | 0.78 | KDM4E (0.55) | METTL3KDM4EMAPTHPGDKMT2A | |
| SCHEMBL862066 | 0.76 | KDM4E (0.51) | METTL3KDM4EMAPTHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | claimed |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2025-01-14 | — | — | US | claimed |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | claimed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | claimed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | claimed |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-13 | — | — | US | claimed |
| EP-4069694-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | Storm Therapeutics Ltd (GB) | 2022-10-12 | — | — | EP | claimed |
| CN-115151540-A | Polyheterocyclic compounds as METTL3 inhibitors | 风暴治疗有限公司 | 2022-10-04 | — | — | CN | claimed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2025-01-14 | — | — | US | disclosed |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| WO-2022254216-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | STORM THERAPEUTICS LTD (GB) | 2022-12-08 | — | — | WO | disclosed |
| EP-4069694-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | Storm Therapeutics Ltd (GB) | 2022-10-12 | — | — | EP | disclosed |
| CN-115151540-A | Polyheterocyclic compounds as METTL3 inhibitors | 风暴治疗有限公司 | 2022-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | METTL3 1/4885KDM4E 62/4885MAPT 3077/4885 |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | METTL3 1/4885KDM4E 872/4885MAPT 2098/4885 |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | METTL3 1/4885KDM4E 107/4885MAPT 3057/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | METTL3 1/4885KDM4E 872/4885MAPT 2098/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | METTL3 1/4885KDM4E 107/4885MAPT 3057/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | METTL3 1/4885KDM4E 717/4885MAPT 4317/4885 |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | METTL3 1/4885KDM4E 107/4885MAPT 3057/4885 |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | METTL3 1/4885KDM4E 107/4885MAPT 3057/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | METTL3 1/4885KDM4E 872/4885MAPT 2098/4885 |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, METTL16, DIMT1 | METTL3 1/4885KDM4E 62/4885MAPT 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.